Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Arena Pharmaceuticals (NQ: ARNA )

66.81 USD -0.93 (-1.37%)
Official Closing Price Updated: 7:17 PM EDT, Apr 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 700,900
Open 67.26
Bid (Size) 66.73 (36)
Ask (Size) 66.80 (2)
Prev. Close 67.74
Today's Range 66.06 - 68.68
52wk Range 44.79 - 90.19
Shares Outstanding 60,334,648
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Arena Pharmaceuticals Releases Second Annual Environmental, Social and Governance (ESG) Report
Arena Pharmaceuticals today announced its second annual ESG report, outlining the Company’s long-term commitment to the betterment of society. 
From Business Wire News Releases
Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial During Late-Breaking Research Session at American Academy of Dermatology Virtual Meeting Experience
Arena Pharmaceuticals to present data from the Phase 2b ADVISE trial at the American Academy of Dermatology VMX on Friday, April 23. 
From Business Wire News Releases

Performance

YTD
-11.31%
-11.31%
1 Month
-8.43%
-8.43%
3 Month
-12.85%
-12.85%
6 Month
-16.85%
-16.85%
1 Year
+38.78%
+38.78%

More News

Read More
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Business Wire News Releases
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Business Wire News Releases
Noteworthy Friday Option Activity: MGNI, FIVE, ARNA
Tags Stocks
From Market News Video
Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial
From Business Wire News Releases
Return On Capital Employed Overview: Arena Pharmaceuticals
Tags News BZI/ROCE Market News
From Benzinga
Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter
From Business Wire News Releases
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Tags Benzinga GENE INVO
From Benzinga
3 Reasons to Avoid Arena Pharmaceuticals -- and 1 Reason to Buy
Tags UTHR ABBV JNJ
From Motley Fool
Arena Pharma's Olorinab Fails To Top Placebo In IBS-Related Abdominal Pain
Tags ARNA Irritable Bowel Syndrome Biotech
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.